O
ALBO

OrbiMed’s Albireo Pharma Inc ALBO Stock Holding History

OrbiMed’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-194,000
Closed -$5.79M – 157
2022
Q1 		$5.79M Buy
+194,000
New +$5.68M 0.09% 116
2020
Q4 		– Sell
-328,385
Closed -$11M – 165
2020
Q3 		$11M Buy
+328,385
New +$9.57M 0.14% 108
2015
Q1 		– Sell
-6,990
Closed -$279K – 147
2014
Q4 		$279K Hold
6,990
– – ﹤0.01% 131
2014
Q3 		$350K Hold
6,990
– – ﹤0.01% 130
2014
Q2 		$453K Sell
6,990
-6,343
-48% -$441K 0.01% 131
2014
Q1 		$1.09M Sell
13,333
-4,915
-27% -$447K 0.01% 135
2013
Q4 		$1.25M Sell
18,248
-11,667
-39% -$855K 0.02% 111
2013
Q3 		$2.83M Sell
29,915
-59,763
-67% -$7.78M 0.05% 115
2013
Q2 		$11.2M Buy
+89,678
New +$9.33M 0.24% 74

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

OrbiMed's ALBO Position: Q2 2022 in Review

OrbiMed sold out of Albireo Pharma Inc (ALBO) in Q2 2022, closing a stake of 194,000 shares — an estimated $5.79M sold.

OrbiMed first reported a position in ALBO in Q2 2013 and held it in 9 quarters. The position peaked at $11.2M in Q2 2013. 103 funds tracked by Wall St. Rank hold ALBO as of Q2 2022.

  • OrbiMed reported no remaining Albireo Pharma Inc position as of Q2 2022 after selling out during the quarter.
  • OrbiMed sold 194,000 Albireo Pharma Inc shares in Q2 2022, an estimated $5.79M.
  • OrbiMed first reported a position in Albireo Pharma Inc in Q2 2013 and held it in 9 quarters.
  • OrbiMed's Albireo Pharma Inc position peaked at $11.2M in Q2 2013.
  • 103 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q2 2022.

Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.